← Leaderboards
Jay Michael Stewart
University Of California, San Francisco
$2,045,950
Attributed
$2,045,950
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $632.7K · FY2017–21$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$2,045,950 · 2
By mechanism
R01$1,580,349 · 1
R34$465,601 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Jennifer Rose-Nussbaumer$10,499,043
- Thuy A Doan$5,287,003
- Anita Sil$24,389,913
- Nisha Acharya$16,289,853
- John Alexander Gonzales$1,263,248
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsPharmaceutical PreparationsFunctional DisorderNovel TherapeuticsEffective TherapyAftercareCrosslinkCustomCorneal EndotheliumCorneal DiseasesCorneal UlcerAntibioticsAntifungal AgentsAntimicrobialCorneal EpitheliumClinically RelevantCollagenAttentionCorneaBodipyCell InjuryAnteriorAbsorptionAcute Toxicity
Grant awards (6)
Oral metformin for non-neovascular age-related macular degeneration$229,145
R34 · FY2021 · EY · contact PI
Ultrasound-enhanced corneal drug delivery$396,250
R01 · FY2020 · EY · contact PI
Oral metformin for non-neovascular age-related macular degeneration$236,456
R34 · FY2020 · EY · contact PI
Ultrasound-enhanced corneal drug delivery$396,250
R01 · FY2019 · EY · contact PI
Ultrasound-enhanced corneal drug delivery$396,250
R01 · FY2018 · EY · contact PI
Ultrasound-enhanced corneal drug delivery$391,599
R01 · FY2017 · EY · contact PI